PubRank

Jeffrey A Bluestone

Author PubWeight™ 292.06‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006 14.33
2 Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 2008 12.45
3 Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002 8.84
4 Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 2009 8.65
5 In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004 8.00
6 Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol 2005 7.44
7 The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005 6.71
8 The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 2008 6.56
9 Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008 6.08
10 Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 2009 5.20
11 Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice. Nature 2007 4.94
12 Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med 2008 4.68
13 TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003 4.40
14 A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005 4.19
15 Control of TH17 cells occurs in the small intestine. Nature 2011 4.03
16 Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 2003 3.86
17 Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med 2005 3.70
18 Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med 2012 3.40
19 Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur J Immunol 2004 3.18
20 Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008 3.18
21 A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 2005 3.07
22 CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007 3.06
23 TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest 2005 3.04
24 Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol 2009 2.93
25 Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev 2008 2.86
26 NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity 2004 2.80
27 Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 2006 2.73
28 Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med 2006 2.68
29 Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity 2003 2.57
30 Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant 2004 2.55
31 Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev 2011 2.54
32 Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes 2008 2.52
33 Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity 2013 2.41
34 Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol 2011 2.39
35 Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology 2007 2.33
36 Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol 2009 2.30
37 Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol 2013 2.13
38 Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev 2006 2.13
39 CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat Med 2008 2.07
40 Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A 2008 2.06
41 Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes 2012 2.02
42 Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev 2009 2.00
43 Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J Clin Invest 2003 1.95
44 Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A 2007 1.90
45 Cell-based therapeutics: the next pillar of medicine. Sci Transl Med 2013 1.83
46 Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013 1.79
47 Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol 2006 1.75
48 How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited. Diabetes 2011 1.74
49 Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. J Clin Invest 2004 1.74
50 Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. J Immunol 2005 1.73
51 Murine pancreatic islet isolation. J Vis Exp 2007 1.68
52 Regulated beta-cell regeneration in the adult mouse pancreas. Diabetes 2007 1.67
53 Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo. J Immunol 2005 1.67
54 A resource for the conditional ablation of microRNAs in the mouse. Cell Rep 2012 1.66
55 Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol 2013 1.65
56 Expression of αvβ8 integrin on dendritic cells regulates Th17 cell development and experimental autoimmune encephalomyelitis in mice. J Clin Invest 2010 1.63
57 Notch 1 signaling regulates peripheral T cell activation. Immunity 2004 1.61
58 Antigen-specific regulatory T cells--ex vivo expansion and therapeutic potential. Semin Immunol 2006 1.55
59 IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proc Natl Acad Sci U S A 2012 1.54
60 The microRNA cluster miR-17∼92 promotes TFH cell differentiation and represses subset-inappropriate gene expression. Nat Immunol 2013 1.50
61 Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes 2006 1.49
62 Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. Nat Immunol 2011 1.49
63 CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. J Mol Cell Biol 2011 1.45
64 Production of α-galactosylceramide by a prominent member of the human gut microbiota. PLoS Biol 2013 1.42
65 Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PLoS One 2011 1.39
66 Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol 2005 1.38
67 Immune therapy and β-cell death in type 1 diabetes. Diabetes 2013 1.33
68 Regulatory T-cell therapy in transplantation: moving to the clinic. Cold Spring Harb Perspect Med 2013 1.29
69 Transplantation of pancreatic islets into the kidney capsule of diabetic mice. J Vis Exp 2007 1.28
70 Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol 2002 1.28
71 Regulatory T cells: stability revisited. Trends Immunol 2011 1.27
72 The yin and yang of interleukin-2-mediated immunotherapy. N Engl J Med 2011 1.26
73 Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol 2009 1.26
74 When ligand becomes receptor--tolerance via B7 signaling on DCs. Nat Immunol 2002 1.25
75 Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J Immunol 2011 1.25
76 Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes. J Immunol 2003 1.25
77 Peripherally induced tregs - role in immune homeostasis and autoimmunity. Front Immunol 2013 1.24
78 CTLA-4 and tolerance: the biochemical point of view. Immunol Res 2003 1.24
79 The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance. Eur J Immunol 2002 1.24
80 Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation 2010 1.23
81 Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2003 1.20
82 T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function. J Immunol 2009 1.16
83 Inability to induce tolerance through direct antigen presentation. Am J Transplant 2002 1.16
84 Spontaneous development of a pancreatic exocrine disease in CD28-deficient NOD mice. J Immunol 2008 1.14
85 MicroRNA regulation of T-cell differentiation and function. Immunol Rev 2013 1.13
86 The immune tolerance network: a new paradigm for developing tolerance-inducing therapies. J Allergy Clin Immunol 2002 1.13
87 Cutting edge: vasostatin-1-derived peptide ChgA29-42 is an antigenic epitope of diabetogenic BDC2.5 T cells in nonobese diabetic mice. J Immunol 2011 1.12
88 Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clin Immunol 2007 1.11
89 Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs. Diabetes 2010 1.10
90 MicroRNA 10a marks regulatory T cells. PLoS One 2012 1.09
91 Achieving antigen-specific tolerance in diabetes: regulating specifically. Int Rev Immunol 2005 1.09
92 CTLA-4 regulates the requirement for cytokine-induced signals in T(H)2 lineage commitment. Nat Immunol 2003 1.06
93 B7-independent inhibition of T cells by CTLA-4. J Immunol 2005 1.05
94 microRNA-17-92 regulates IL-10 production by regulatory T cells and control of experimental autoimmune encephalomyelitis. J Immunol 2013 1.05
95 Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J Clin Invest 2006 1.05
96 Distinct effector mechanisms in the development of autoimmune neuropathy versus diabetes in nonobese diabetic mice. J Immunol 2005 1.04
97 Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. PLoS One 2010 1.03
98 Mechanisms of tolerance. Immunol Rev 2011 1.01
99 B cell depletion: a novel therapy for autoimmune diabetes? J Clin Invest 2007 1.00
100 Expression of CTLA-4 and FOXP3 in cis protects from lethal lymphoproliferative disease. Eur J Immunol 2007 1.00
101 The role of CD28 and CTLA4 in the function and homeostasis of CD4+CD25+ regulatory T cells. Novartis Found Symp 2003 1.00
102 Breakdown in peripheral tolerance in type 1 diabetes in mice and humans. Cold Spring Harb Perspect Med 2012 1.00
103 Directed evolution of a single-chain class II MHC product by yeast display. Protein Eng 2003 0.99
104 A novel myelin P0-specific T cell receptor transgenic mouse develops a fulminant autoimmune peripheral neuropathy. J Exp Med 2009 0.99
105 CD28-inducible transcription factor DEC1 is required for efficient autoreactive CD4+ T cell response. J Exp Med 2013 0.98
106 CTLA-4 regulates expansion and differentiation of Th1 cells following induction of peripheral T cell tolerance. J Immunol 2004 0.97
107 CD28/B7 regulation of anti-CD3-mediated immunosuppression in vivo. J Immunol 2003 0.95
108 Importance of IL-10 for CTLA-4-mediated inhibition of tumor-eradicating immunity. J Immunol 2004 0.94
109 Type 1 diabetes immunotherapy: is the glass half empty or half full? Sci Transl Med 2011 0.93
110 The B7-independent isoform of CTLA-4 functions to regulate autoimmune diabetes. J Immunol 2013 0.93
111 T cells in the control of organ-specific autoimmunity. J Clin Invest 2015 0.93
112 Immunotherapy of insulin-dependent diabetes mellitus. Curr Opin Immunol 2002 0.92
113 The Src family kinase Fyn mediates signals induced by TCR antagonists. J Immunol 2002 0.92
114 Constitutive expression of B7-1 on B cells uncovers autoimmunity toward the B cell compartment in the nonobese diabetic mouse. J Immunol 2007 0.91
115 Requirements for prolongation of allograft survival with regulatory T cell infusion in lymphosufficient hosts. J Surg Res 2011 0.91
116 Clinical trials of transplant tolerance: slow but steady progress. Am J Transplant 2003 0.91
117 Plasmacytoid DCs and T(reg) cells: casual acquaintance or monogamous relationship? Nat Immunol 2006 0.91
118 Insulin receptor substrate-2 in beta-cells decreases diabetes in nonobese diabetic mice. Endocrinology 2009 0.90
119 Small RNA regulators of T cell-mediated autoimmunity. J Clin Immunol 2010 0.89
120 Beta-cell replacement for type I diabetes. Annu Rev Med 2004 0.89
121 Evidence that Cd101 is an autoimmune diabetes gene in nonobese diabetic mice. J Immunol 2011 0.88
122 An important role of CD80/CD86-CTLA-4 signaling during photocarcinogenesis in mice. J Immunol 2005 0.87
123 Is antigen specificity of autoreactive T cells the key to islet entry? Immunity 2009 0.85
124 Bringing transplantation tolerance into the clinic: lessons from the ITN and RISET for the Establishment of Tolerance consortia. Curr Opin Organ Transplant 2010 0.85
125 Inhibition of VEGFR-2 reverses type 1 diabetes in NOD mice by abrogating insulitis and restoring islet function. Diabetes 2013 0.85
126 Altered balance between effector T cells and FOXP3+ HELIOS+ regulatory T cells after thymoglobulin induction in kidney transplant recipients. Transpl Int 2012 0.84
127 Cutting Edge: a novel, human-specific interacting protein couples FOXP3 to a chromatin-remodeling complex that contains KAP1/TRIM28. J Immunol 2013 0.84
128 The role of X-linked FOXP3 in the autoimmune susceptibility of Turner Syndrome patients. Clin Immunol 2009 0.84
129 NK cells are not required for spontaneous autoimmune diabetes in NOD mice. PLoS One 2012 0.83
130 Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells. J Immunol 2002 0.82
131 Lethal effect of CD3-specific antibody in mice deficient in TGF-beta1 by uncontrolled flu-like syndrome. J Immunol 2009 0.82
132 Regulatory T cells directed to the site of the action. Proc Natl Acad Sci U S A 2009 0.82
133 Distinct genetic control of autoimmune neuropathy and diabetes in the non-obese diabetic background. J Autoimmun 2013 0.82
134 DGCR8-mediated production of canonical microRNAs is critical for regulatory T cell function and stability. PLoS One 2013 0.81
135 Peptide specific amelioration of T cell mediated pathogenesis in murine type 1 diabetes. Clin Immunol 2004 0.81
136 Sensory neurons link the nervous system and autoimmune diabetes. Cell 2006 0.80
137 FK506 causes cellular and functional defects in human natural killer cells. J Leukoc Biol 2010 0.80
138 CTLA-4Ig is finally making it: a personal perspective. Am J Transplant 2005 0.80
139 Altered cutaneous immune parameters in transgenic mice overexpressing viral IL-10 in the epidermis. J Clin Invest 2003 0.79
140 CTLA-4: acting at the synapse. Mol Interv 2002 0.79
141 Autoimmunity. Curr Opin Immunol 2009 0.79
142 A peptide of glutamic acid decarboxylase 65 can recruit and expand a diabetogenic T cell clone, BDC2.5, in the pancreas. J Immunol 2005 0.79
143 Safer, longer-lasting regulatory T cells with beta-catenin. Nat Med 2008 0.78
144 Clusterin synergizes with IL-2 for the expansion and IFN-γ production of natural killer cells. J Leukoc Biol 2010 0.78
145 Suppression of human anti-porcine natural killer cell xenogeneic responses by combinations of monoclonal antibodies specific to CD2 and NKG2D and extracellular signal-regulated kinase kinase inhibitor. Immunology 2010 0.78
146 Tyrosine 201 of the cytoplasmic tail of CTLA-4 critically affects T regulatory cell suppressive function. Eur J Immunol 2014 0.77
147 Differential roles of costimulatory signaling pathways in type 1 diabetes mellitus. Rev Diabet Stud 2005 0.77
148 A mimic of viral double-stranded RNA triggers fulminant type 1 diabetes-like syndrome in regulatory T cell-deficient autoimmune diabetic mouse. J Immunol 2011 0.76
149 Single step isolation and activation of primary CD3+ T lymphocytes using alcohol-dispersed electrospun magnetic nanofibers. Nano Lett 2012 0.76
150 Targeting ABL-IRE1α Signaling Spares ER-Stressed Pancreatic β Cells to Reverse Autoimmune Diabetes. Cell Metab 2017 0.75
151 Correction: CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis. J Immunol 2016 0.75
152 Corrigendum: Is autoimmunity the Achilles' heel of cancer immunotherapy? Nat Med 2017 0.75
153 Pillars article: CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994. 1: 405-413. J Immunol 2011 0.75